Organon & Co. (NYSE:OGN) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Organon & Co. (NYSE:OGN) have earned a consensus recommendation of “Reduce” from the seven brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.40.

Several equities analysts recently weighed in on OGN shares. Barclays increased their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. BNP Paribas Exane reiterated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th.

Insiders Place Their Bets

In other Organon & Co. news, SVP Lynette Holzbaur purchased 26,448 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This represents a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On Organon & Co.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Private Management Group Inc. grew its stake in Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares during the period. Gotham Asset Management LLC grew its stake in Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock valued at $39,657,000 after acquiring an additional 1,007,691 shares during the period. Vanguard Group Inc. grew its stake in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after acquiring an additional 3,650,860 shares during the period. UBS Group AG grew its stake in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the period. Finally, Kahn Brothers Group Inc. grew its stake in Organon & Co. by 3.6% in the 3rd quarter. Kahn Brothers Group Inc. now owns 3,616,845 shares of the company’s stock valued at $38,628,000 after acquiring an additional 126,695 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Up 0.1%

Organon & Co. stock opened at $13.46 on Wednesday. The stock has a 50-day moving average price of $11.61 and a 200 day moving average price of $8.90. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of 14.47, a price-to-earnings-growth ratio of 1.24 and a beta of 1.55. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.49. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the company posted $1.02 EPS. Organon & Co.’s quarterly revenue was down 3.5% compared to the same quarter last year. Sell-side analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, May 11th. Organon & Co.’s dividend payout ratio is 8.60%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.